Potential Anti-cancer Activity
Nelfinavir were under investigation, in 2009, for potential use as an anti-cancer agent. When applied to cancer cells in culture (in vitro), it can inhibit the growth of a variety cancer types and can trigger cell death (apoptosis). When Nelfinavir was given to laboratory mice with tumors of the prostate or of the brain, it could suppress tumor growth in these animals. In vitro tests showed it may work well with sorafenib
In the United States, several clinical trials were conducted in 2008 that sought to verify whether nelfinavir is effective as a cancer therapeutic agent in humans. In some of these trials, nelfinavir was used alone in monotherapy fashion, whereas in others it was combined with other modes of cancer therapy, such as well-established chemotherapeutic agents or radiation therapy.
Good phase I results were obtained for locally advanced pancreatic cancer.
In the UK, in 2010, a phase I trial (of nelfinavir with radiotherapy), on patients with inoperable cancer, showed a doubling of survival times, and six patients had tumor regression to the extent that they became operable.
Read more about this topic: Nelfinavir
Famous quotes containing the words potential and/or activity:
“The traditional American husband and father had the responsibilities—and the privileges—of playing the role of primary provider. Sharing that role is not easy. To yield exclusive access to the role is to surrender some of the potential for fulfilling the hero fantasy—a fantasy that appeals to us all. The loss is far from trivial.”
—Faye J. Crosby (20th century)
“In communist society, where nobody has one exclusive sphere of activity but each can become accomplished in any branch he wishes, society regulates the general production and thus makes it possible for me to do one thing today and another tomorrow, to hunt in the morning, fish in the afternoon, rear cattle in the evening, criticize after dinner, just as I have a mind, without ever becoming hunter, fisherman, shepherd or critic.”
—Karl Marx (1818–1883)